IP Library Granted Patent US 7,883,705
Granted Patent B2
US 7,883,705 · App. 12/030,593 · Granted Feb 8, 2011

Anti FGF23 antibody and a pharmaceutical composition comprising the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,883,705
App. No.
12/030,593
Granted
Feb 8, 2011
Kind
B2
Abstract

To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

Claims (10)

1. An isolated antibody against human FGF23, comprising a heavy chain variable region or a light chain variable region having the same amino acid sequence as an antibody produced by hybridoma C10 (Accession No. FERM BP-10772).

2. An isolated antibody against human FGF23, comprising a heavy chain variable region comprising an amino acid sequence from the amino acid at position 20 of SEQ ID NO: 12 to the amino acid at position 136 of SEQ ID NO: 12 or a light chain variable region comprising an amino acid sequence from the amino acid at position 23 of SEQ ID NO: 14 to the amino acid at position 128 of SEQ ID NO: 14.

3. The antibody of claim 2 , wherein (A) the antibody against human FGF23 comprises a heavy chain variable region and a light chain variable region and (B) the heavy chain variable region comprises an amino acid sequence from the amino acid at position 20 of SEQ ID NO: 12 to the amino acid at position 136 of SEQ ID NO: 12 and the light chain variable region comprises an amino acid sequence from the amino acid at position 23 of SEQ ID NO: 14 to the amino acid at position 128 of SEQ ID NO: 14.

4. An isolated antibody against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

5. The isolated antibody against human FGF23 of claim 1 , wherein the class of the antibody is selected from the group consisting of IgG, IgA, IgE, and IgM.

6. The isolated antibody against human FGF23 of claim 5 , wherein the subclass of the IgG antibody is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

7. A pharmaceutical composition, comprising as an active ingredient, the isolated antibody against human FGF23 of claim 1 .

8. A hybridoma C10 (Accession No. FERM BP-10772).

9. An isolated antibody against human FGF23, comprising a heavy chain variable region and a light chain variable region having the same amino acid sequence as an antibody produced by hybridoma C10 (Accession No. FERM BP-10772), wherein the subclass of said antibody is IgG1.

10. An isolated antibody against human FGF23, comprising a heavy chain variable region comprising an amino acid sequence from the amino acid sequence at position 20 of SEQ ID NO:12 to the amino acid at position 136 of SEQ ID NO:12 and a light chain variable region comprising an amino acid sequence from the amino acid at position 23 of SEQ ID NO:14 to the amino acid at position 128 of SEQ ID NO:14, wherein the subclass of said antibody is IgG1.

Assignments (4)
CHANGE OF NAME Recorded Oct 21, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050777/0905 →
MERGER Recorded Mar 23, 2009
From: KIRIN PHARMA CO., LTD.
To: KYOWA HAKKO KOGYO CO., LTD.
Reel/Frame 022435/0527 →
CHANGE OF NAME Recorded Mar 23, 2009
From: KYOWA HAKKO KOGYO CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 022435/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2008
From: YAMAZAKI, YUJI; URAKAWA, ITARU; YOSHIDA, HITOSHI; AONO, YUKIKO; YAMASHITA, TAKEYOSHI; SHIMADA, TAKASHI; HASEGAWA, HISASHI
To: KIRIN PHARMA KABUSHIKI KAISHA
Reel/Frame 021715/0365 →